Although emerging evidence has suggested the relationship of chronic obstructive pulmonary disease with atrial fibrillation (AF), little is known about whether acute exacerbation of chronic obstructive pulmonary disease (AECOPD) increases the risk of repeated AF-related healthcare utilization.
A trial fibrillation (AF) is a major public health problem that affects 6 million Americans 1 and accounts for 540 000 emergency department (ED) visits and 400 000 hospitalizations annually. 1 Among patients with AF, one-third of patients are hospitalized each year. 2 Additionally, with aging in the population, the number of AF-related hospitalization has increased by 23% during the last decade. 3 Because of its clinical and public health importance, 3 understanding risk factors for AF-related morbidities is instrumental to developing preventive strategies.
In parallel to AF, chronic obstructive pulmonary disease (COPD) is another major public health problem, with 600 000 hospitalizations for acute exacerbation of COPD (AECOPD) in the United States each year. 1 Recent studies have shown the linkage between COPD and AF. For example, cohort studies have reported that COPD is a risk factor for new-onset AF. [4] [5] [6] [7] In addition, another cohort study revealed that in patients with paroxysmal AF, concurrent COPD is a risk factor for AF progression, from paroxysmal AF to persistent AF. 8 These emerging evidences suggest the relationship of COPD (as a chronic morbidity) with both the development and progression of AF. Despite the clinical and physiological importance of AECOPD, little is known about whether, in patients with existing AF, AECOPD is associated with a higher risk of AF-related morbidities.
To address the knowledge gap, we investigated the temporal association between AECOPD-and AF-related ED visits or hospitalizations. Specifically, we hypothesized, among adults with AF, that an AECOPD hospitalization increases the rate of AF-related ED visits or hospitalizations within 1-year period after the hospitalization, compared with that in the pre-AECOPD hospitalization period.
METHODS

Study Design and Setting
We performed a self-controlled case series study using the Healthcare Cost and Utilization Project (HCUP) State ED Databases (SEDD) and State Inpatient Databases (SID). Briefly, we created a cohort of patients with AF and then compared each subject's rate of AF-related ED visits or hospitalizations during a 450-day period (ie, 90-day period before and 360-day period after AECOPD). Based on the data use agreement, the datasets and study materials will not be made publically available. The self-controlled case series design allows each subject to serve as his/her own control. Therefore, it minimizes confounding by time-invariant factors and removes interperson variations. The data were extracted from the HCUP SEDD and SID of geographically diverse 5 US states (California, Florida, Nebraska, New York, and Utah), from January 2007 through December 2012. The HCUP is the largest collection of longitudinal hospital care data in the United States, with all-payer, encounter-level information. 9 The SEDD encompasses all ED visits, including treat-and-release encounters and transfers; the SID captures all hospitalizations, regardless of source or disposition, from acute care, nonfederal, general, and other specialty hospitals within the participating states. Taken together, the SEDD and SID capture all ED visits regardless of disposition and all hospitalizations regardless of admission source. Additional details of the HCUP SEDD and SID can be found elsewhere. 9 The 5 states were selected for their geographical diversity, data quality, and chiefly because their data contain unique subject identifiers that enable us to follow specific subject longitudinally. The Institutional Review Board of the Massachusetts General Hospital approved this study.
Study Population
First, we identified all adults who had at least 1 as well as an outcome-at least 1 ED visit or hospitalization for AF-during 2008 to 2011. To minimize the potential misclassification of COPD, we excluded patients aged <40 years because they are less likely to have COPD. 10, 11 We excluded patients who live outside of the study states, those who died during the index hospitalization, and those who left the hospital against medical advice. Selection of study samples is shown in Figure 1 .
Measurements
The databases recorded patient characteristics, including demographics (age, sex, and race/ethnicity), primary insurance type (payer), quartiles for estimated household
WHAT IS KNOWN?
• Longitudinal cohort studies have shown that chronic obstructive pulmonary disease (COPD) is a risk factor for new-onset atrial fibrillation (AF).
• In patients with paroxysmal AF, concurrent COPD is a risk factor for AF progression, from paroxysmal AF to persistent AF.
WHAT THE STUDY ADDS?
• After the hospitalization for acute exacerbation of COPD (AECOPD), patients with existing AF had an ≈2-fold increased rate ratio of emergency department visits or hospitalizations for AF during the first 90-day post-AECOPD period.
• The elevated risk of AF-related ED visits or hospitalizations decreased to the baseline level after the first 90-day post-AECOPD period.
income, patient residence, ICD-9-CM diagnostic and procedure codes, and patient comorbidities (29 Elixhauser comorbidity measures). We determined the baseline characteristics at the time of hospitalization for AECOPD.
Primary Exposure
The primary exposure was hospitalization for AECOPD as defined above. [10] [11] [12] For the analysis, we used the data of the first AECOPD hospitalization for each individual. To isolate the effects of a single AECOPD hospitalization on the outcomes, we excluded patients who had an additional AECOPD hospitalization during the follow-up period.
Outcome Measure
The outcome measure of interest was the composite of ED visit or hospitalization with a primary diagnosis of AF 3, [13] [14] [15] during the 90-day period preceding the AECOPD hospitalization and the 360-day period after the hospitalization.
Statistical Analysis
We used a self-controlled case series method to perform within-person comparisons among those who experienced both the exposure (ie, hospitalization for AECOPD) and outcome (ED visit or hospitalization for AF) during a 450-day period. No separate control group was necessary because this method allows each patient to function as his or her own control. 16 We computed the rate of AF-related ED visits or hospitalizations for 450 consecutive days (90 days before and 360 days after the AECOPD hospitalization; Figure I in the Data Supplement). We described the rate of AF-related ED visits or hospitalizations-by computing the number of outcome events per 100 person-monthsat each 90-day interval during the 450-day period (90 days before and 360 days after the AECOPD hospitalization). To compare each patient's rate of the outcomes with pre-AECOPD days 1 to 90 as the reference period, we fit conditional Poisson regression models calculating the rate ratios (RRs) and the 95% CIs for post-AECOPD days 1 to 90, days 91 to 180, days 181 to 270, and days 271 to 360. For the graphic presentation, we also calculated the RRs in 30-day intervals with pre-AECOPD days 61 to 90 as the reference period.
We performed a series of sensitivity analyses to examine the robustness of our inference. First, we repeated the analysis with stratification by age category (age, 40-64 and ≥65 years) sex, and presence of AF in any diagnostic field at the index hospitalization. Second, to account for the seasonal variation of AF, 17 we repeated the analysis with stratification by season of the index hospitalization for AECOPD: spring (March to May), summer (June to August), fall (September to November), and winter (December to February). 18 Third, to address the potential misclassification of AF, we repeated the analysis including the patients with a primary diagnosis of heart failure (ICD-9-CM diagnosis codes of 402. 01 19, 20 and secondary diagnosis of AF. Fourth, to account for the potential effects of separate mildto-moderate AECOPD episodes (in addition to the AECOPD hospitalization) on the outcomes during the reference period, we repeated the analysis limiting to the patients who did not have an AECOPD-related ED visit (treat and release) during the reference period. Fifth, we performed the analysis including the patients with multiple hospitalizations for AECOPD during the follow-up period. Sixth, to account for the loss to follow-up, we repeated the analysis limiting to those who had any healthcare utilization after the post-AECOPD day of 360 (ie, those who are known to be alive for at least 360 days after the AECOPD hospitalization). Last, we fit conditional logistic regression modeling the outcome as a binomial variable (instead of a count variable) in 90-day intervals. All analyses used STATA 14.0 (STATA Corp, College Station, TX). All P values were 2 tailed, with P<0.05 considered statistically significant.
RESULTS
Patient Characteristics
We identified all adults with existing AF who were hospitalized for AECOPD (the exposure) during 2008 to 2011 in the 5 US states (n=25 227). Of these, a total of 1547 patients had an ED visit or hospitalization for AF (the outcome) during a 450-day period. From these samples, we excluded 603 patients who had an additional AECOPD hospitalization, leaving 944 patients eligible for the analysis (Figure 1) . Table 1 summarizes the patient characteristics. The median age was 77 years (interquartile range, 67-83 years), 59% were women, and 79% were non-Hispanic whites; 51% had congestive heart failure, 35% had diabetes mellitus, and 71% had hypertension.
Associations Between AECOPD Hospitalization and Rate of AF-Related Acute Care Use Figure 2 depicts the rate of ED visits or hospitalizations for AF during the pre-and post-AECOPD periods by 30-day intervals. In the reference period (ie, pre-AECO-PD days 1-90), the rate of AF-related ED visits or hospitalizations was 7.3 per 100 person-months (Table 2 ). In the first 90-day period immediately after the AECOPD hospitalization (ie, post-AECOPD days 1-90), the rate increased significantly (14.1 per 100 person-months) with a corresponding RR of 1.93 (95% CI, 1.63-2.29; P<0.001). Then, in the subsequent 90-day period (ie, post-AECOPD days 91-180), the rate decreased to the reference level (7.5 per 100 person-months) with a corresponding RR of 1.03 (95% CI, 0.85-1.25; P=0.77). Similarly, the rate remained at the reference level in the post-AECOPD periods of 181 to 270 days (6.1 per 100 person-months; RR, 0.84; 95% CI, 0.68-1.03; P=0.09) and 271 to 360 days (6.6 per 100 person-months; RR, 0.90; 95% CI, 0.73-1.10; P=0.29).
Sensitivity Analyses
The observed temporal patterns persisted with stratification by age (Table I in (Table IV in the Data Supplement). Likewise, in the sensitivity analysis including the patients with a primary diagnosis of heart failure and secondary diagnosis of AF, the observed temporal patterns persisted (Table V in the Data Supplement). Likewise, in the analysis limiting to the patients who did not have an ED visit for AECOPD during the reference period, the result did not change materially (Table VI in the Data Supplement) . Similarly, in the analysis including the patients with multiple hospitalizations for AECOPD during the follow-up period, the results were consistent with the main findings (Table VII in the Data Supplement). Furthermore, in the subgroup analysis limiting to the patients who were known to be alive at least 360 days after the AECOPD hospitalization, the results were also consistent with the main findings (Table VIII in the Data Supplement). Last, the significant association also persisted with modeling the outcome as a binomial response, for example, the odds ratio of the outcome event was 2.55 (95% CI, 2.07-3.14; P<0.001; Table IX in the Data Supplement) in the post-AECOPD days 1 to 90.
DISCUSSION
In this self-controlled case series study using a population-based data set of adults with existing AF, we found that, after hospitalization for AECOPD (the exposure), there was a ≈2-fold increase in the rate of ED visits or hospitalizations for AF (the outcome) in the first 90-day post-AECOPD period. The elevated rate decreased to the baseline thereafter. These observed temporal relationships of AECOPD with AF-related ED visits or hospitalizations persisted across the different patient subgroups and statistical assumptions. To the best of our knowledge, this is the first study that has investigated the temporal association between AECOPD and AFrelated acute morbidities. To date, the literature has shown the relations of COPD as a chronic morbidity (not AECOPD) with AF. For example, having COPD is a risk factor for incident AF. [4] [5] [6] [7] In a cohort study of the US general population, individuals with the lowest quartile of forced expiratory volume in 1 second had a 1.5-fold increased risk of incident AF compared with those with the highest quartile of forced expiratory volume in 1 second. In a study of 173 patients hospitalized for AECOPD and hypercapnia, those with concurrent AF had a lower FEV1.0%, higher PaCO2, and higher pulmonary artery systolic pressure, compared with those without AF. 7 In addition, studies have reported that comorbid COPD is associated with clinical AF progression, 8 failure of AF treatment, [21] [22] [23] and overall mortality. 24, 25 Indeed, a cohort study of 1219 patients with paroxysmal AF demonstrated that concurrent COPD was a risk factor for progression to persistent AF during the 1-year follow-up period. 8 Another cohort study also showed that COPD was associated with a higher recurrence of AF after their first catheter ablation. 22 Furthermore, an analysis of patients with AF in the In the subsequent periods, the RR did not differ significantly from that in the reference period. ARISTOTLE study (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) showed that patients with COPD had a 1.6-fold higher risk of all-cause mortality compared with those without COPD. 24 These evidences collectively suggest the associations of chronic morbid COPD and AF morbidity. Our findings corroborate these earlier studies and extend them by demonstrating the temporal association between AECOPD-important events in the disease course of COPD-and an increased risk of AF-related ED visits and hospitalizations.
The mechanisms that underlie our observation are likely multifactorial. A potential explanation includes AECOPD-related elevated systemic inflammatory status. [26] [27] [28] [29] Prior research has indicated that inflammation plays an important role in presence, 30 incidence, 31 and prognosis 32 of AF. Alternatively, hypoxemia may be another pathological mechanism for worse AF control. Recent studies have shown that hypoxia-inducible factor-1α promotes atrial structural remodeling leads to AF. 33, 34 Another possible mechanism is ventricular dysfunction 35 with increased atrial afterload 36 in patients with AECOPD. Last, medications for AECOPD management (eg, β-agonists), through modifying the atrioventricular nodal conduction, 37, 38 potentially affect AF control; these medications may be held in this study population with COPD. These data should facilitate further investigations into the development of preventive strategies on AF-related morbidities in patients with COPD.
Potential Limitations
Our study has several potential limitations. First, because we used administrative datasets, there may be misclassifications, such as misdiagnosis of COPD and AF. However, the HCUP data are rigorously tested, 15, 39 and these have been widely used to investigate their morbidities. 10, 11, 15 In addition, the literature has also shown that the ICD-9-CM diagnostic codes for COPD have a specificity of 99% and positive predictive value of 90%. 40 Similarly, patients with latent AF might have been misclassified as patients without AF. Yet, studies showed that the codes for AF have a positive predictive value of 90%. 41, 42 Second, because the datasets did not contain detailed clinical information (eg, medications), the current analyses were unable to address the longitudinal changes in the risk factors for AF during the study periods (eg, changes in AF medications, severity of concurrent cardiac diseases) and the specific type of AF, that is, persistent, permanent, and paroxysmal AF. However, the self-controlled case series method enabled us to address time-invariant confounders (eg, genetics), regardless of measured or unmeasured. Third, patients might have been lost to follow-up after the hospitalization for AECOPD. Yet, the sensitivity analysis limiting to those who are known to be alive at least 360 days after the hospitalization showed the consistent results. Fourth, because our study focused on patients with AF hospitalized for AECOPD, generalizing our inferences beyond this population (eg, patients without existing AF, those with mild-to-moderate AECO-PD) requires caution. However, the study population accounts for a large societal burden 1, 3 and hence is the one for which the development of preventive strategies is urgently needed. Finally, the studied data are not a random sample of all individuals with COPD and AF in the United States However, the 5 study states are geographically diverse and represent ≈27% of the US population.
Conclusions
In this self-controlled case series study using population-based data of adults with AF, we found that after the hospitalization for AECOPD, there was a ≈2-fold increase in the rate of ED visits or hospitalizations for AF during the first 90-day post-AECOPD period. The rate then declined to the baseline levels. The observed temporal relationship of AECOPD with AF-related acute morbidities persisted across the different subgroups and statistical assumptions. For clinicians, our findings underscore the importance of preventing AF-related events in patients with AF who experience AECOPD. For researchers, the data should advance further investigations into the mechanisms underlying the AECOPD-AF linkage to develop targeted therapeutic interventions in this population with large healthcare utilization.
Disclosures
Dr Camargo has performed chronic obstructive pulmonary disease-related consultation for AstraZeneca, GlaxoSmithKline, and Mereo. The other authors report no conflicts.
